Chimeric Therapeutics Limited (ASX:CHM)
Australia
· Delayed Price · Currency is AUD 0.0020
0.00 (0.00%)
Apr 21, 2026, 3:37 PM AEST
Chimeric Therapeutics Revenue
Chimeric Therapeutics had revenue of 2.62M AUD in the half year ending December 31, 2025, a decrease of -76.12%. This brings the company's revenue in the last twelve months to 9.75M, up 377.63% year-over-year. In the fiscal year ending June 30, 2025, Chimeric Therapeutics had annual revenue of 12.68M with 70.09% growth.
Revenue (ttm)
9.75M
Revenue Growth
+377.63%
P/S Ratio
0.95
Revenue / Employee
n/a
Employees
n/a
Market Cap
9.28M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Immuron | 7.48M |
| AdAlta | 608.07K |
| Invex Therapeutics | 229.08K |
| Biotron | -868.00 |
| Tissue Repair | 3.38M |
| Bio-Gene Technology | 390.63K |
| Vectus Biosystems | 89.96K |
| Nexalis Therapeutics | 986.43K |